European review for medical and pharmacological sciences最新文献

{"title":"Retraction Note.","authors":"","doi":"10.26355/eurrev_202509_37398","DOIUrl":"https://doi.org/10.26355/eurrev_202509_37398","url":null,"abstract":"<p><p>The Editor-in-Chief, in accordance with the Publisher, has retracted the following articles published between 2017 and 2020 on the grounds of figure duplication and manipulation, subsequent to concerns raised on PubPeer: 1. Y.-X. Liu, Y. Sun. MMP-2 participates in the sclera of guinea pig with form-deprivation myopia via IGF-1/STAT3 pathway. Eur Rev Med Pharmacol Sci 2018; 22 (9): 2541-2548-DOI: 10.26355/eurrev_201805_14945-PMID: 29771404. Duplications were found in panels B and C of Figure 1 and in the right eye/left eye of the Western Blot in Figure 3A and a previously published article. 2. W.-Y. Niu, L. Chen, P. Zhang, H. Zang, B. Zhu, W.-B. Shao. Circ_0091579 promotes proliferative ability and metastasis of liver cancer cells by regulating microRNA-490-3p. Eur Rev Med Pharmacol Sci 2019; 23 (23): 10264-10273-DOI: 10.26355/eurrev_201912_19664-PMID: 31841181. Duplications were found in Figures 2D and 4D with previously published articles. 3. G.-Z. Tan, M. Li, X. Tan, M.-L. Shi, K. Mou. MiR-491 suppresses migration and invasion via directly targeting TPX2 in breast cancer. Eur Rev Med Pharmacol Sci 2019; 23 (22): 9996-10004-DOI: 10.26355/eurrev_201911_19566-PMID: 31799669. A duplication was found in panels D and E of Figure 2. 4. L. Shi, Y. Yuan, H.-Y. Li. MicroRNA-139-3p suppresses growth and metastasis of glioblastoma via inhibition of NIN1/RPNI2 binding protein 1 homolog. Eur Rev Med Pharmacol Sci 2019; 23 (10): 4264-4274-DOI: 10.26355/eurrev_201905_17931-PMID: 31173298. A duplication was found in panels A and B of Figure 2. 5. D.-J. Yu, Y.-H. Li, M. Zhong. LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2019; 23 (11): 4800-4806-DOI: 10.26355/eurrev_201906_18065-PMID: 31210311. Several duplications were found in panels A, B, C, D, E, and F of Figure 3 with previously published articles, resulting in complete manipulation. Duplications were also found in panel A of Figure 2 with a previously published article. 6. X.-Z. Wang, Z.-X. Yu, B. Nie, D.-M. Chen. Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway. Eur Rev Med Pharmacol Sci 2019; 23 (15): 6672-6682-DOI: 10.26355/eurrev_201908_18558-PMID: 31378910. Duplications were found in the Western Blots of Figure 3 with a previously published article, as well as in the Western Blot of Figure 4. A duplication was also detected in panel C of Figure 2. 7. K. Chen, A. Abuduwufuer, H. Zhang, L. Luo, M. Suotesiyali, Y. Zou. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci 2019; 23 (16): 6935-6943-DOI: 10.26355/eurrev_201908_18733-PMID: 31486493. Duplications were found in panel C of Figure 3 with previously published articles, as well as between panels C of Figure 2. 8. D. Xu, R. Liao, X.-X. Wang, Z. Cheng. Effects of miR-155 on hypertensive rats via regu","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 9","pages":"414-415"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficiency of tapering programmed intermittent epidural analgesia in video-assisted thoracic surgery: a double-blind, prospective, randomized study.","authors":"A Matsumoto, S Satomi, S Narasaki, S Kamiya, H Miyoshi, Y M Tsutsumi","doi":"10.26355/eurrev_202509_37404","DOIUrl":"https://doi.org/10.26355/eurrev_202509_37404","url":null,"abstract":"<p><p>OBJECTIVE: Programmed intermittent epidural bolus (PIEB) is an effective analgesic method owing to the redistribution of the drug solution, which leads to a gradual improvement in postoperative pain over time. This study aimed to compare the postoperative analgesic effects of patient-controlled epidural analgesia (PCEA) with those of tapering PIEB (t-PIEB), in which the drug dosage is decreased over time, and continuous epidural infusion (CEI). MATERIALS AND METHODS: Patients undergoing video-assisted thoracoscopic surgery (VATS) with general and epidural anesthesia were randomized in a 1:1 ratio into the t-PIEB and CEI groups. Patients in the t-PIEB group received 3 mL of 0.2% ropivacaine from the pump every hour, whereas those patients in the CEI group received the same drug solution continuously at a rate of 3 mL/h. In both groups, a 2-mL bolus of 0.2% ropivacaine was administered postoperatively, with additional PCEA as needed. In the t-PIEB group, the dosage was gradually decreased to 2 mL/dose after 25 h and to 1 mL/dose after 49 h. The primary endpoint was the number of times the patient pressed the PCA button at 24, 48, and 72 h. RESULTS: No significant difference was observed in the frequency of PCA button pressing between the two groups during the observation period. The t-PIEB group had a significantly lower usage of ropivacaine. CONCLUSIONS: Nt-PIEB could have analgesic effects comparable to those of CEI for postoperative pain following VATS with less medication use.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-20-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 9","pages":"434-442"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and electrophysiological features of foodborne botulism: a retrospective case series.","authors":"F Al-Hussain, H Albulaihi, R Alhammad, S Alsubaie, A Alhammad, S Bashir","doi":"10.26355/eurrev_202509_37400","DOIUrl":"https://doi.org/10.26355/eurrev_202509_37400","url":null,"abstract":"<p><p>BACKGROUND: Foodborne botulism is a rare but potentially serious and lethal disease that is considered a threat to public health systems across the globe. Botulism is a paralytic disorder caused by the neurotoxin, produced by Clostridium botulinum, which acts upon peripheral cholinergic nerve terminals by inhibiting acetylcholine release, subsequently causing denervation to muscle fibers. CASE SERIES: In April 2024, an outbreak of foodborne botulism was reported in Riyadh, Saudi Arabia, following consumption of contaminated fast food. Four patients were affected: two females and two males, aged 14 to 21 years. All patients developed neurological symptoms, including cranial nerve involvement, dysphagia, and generalized weakness. Three patients progressed to severe hypercapnic respiratory failure requiring prolonged mechanical ventilation. Electrophysiological studies demonstrated characteristic findings of presynaptic neuromuscular junction dysfunction. CONCLUSIONS: This case series adds to existing knowledge by providing detailed descriptions of the clinical course, neurological examination findings, and electrodiagnostic features of foodborne botulism cases in Saudi Arabia. Our findings highlight that, despite early antitoxin administration, patients can develop prolonged neuromuscular weakness requiring extended mechanical ventilation. This underscores the importance of considering botulism in the differential diagnosis of acute flaccid paralysis and the need for timely electrophysiological evaluation to guide management and prognosis.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-ABSTRACT-19.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 9","pages":"416-424"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug repurposing of dimethyl fumarate in Parkinson's disease: a promising disease-modifying strategy.","authors":"M Salvadè, F Gardoni","doi":"10.26355/eurrev_202509_37406","DOIUrl":"https://doi.org/10.26355/eurrev_202509_37406","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and pathological aggregation of a-synuclein. Despite advancements in symptomatic treatment, there is a critical unmet need for disease-modifying therapies capable of halting or slowing disease progression. Drug repurposing offers an efficient, cost-effective strategy to identify new treatments by leveraging the established safety and pharmacokinetic profiles of existing compounds. Dimethyl fumarate (DMF), an FDA-approved drug for multiple sclerosis and psoriasis, has recently emerged as a promising neuroprotective agent in PD research. Preclinical studies consistently demonstrate that DMF exerts beneficial effects in both in vitro and in vivo PD models, primarily via activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Through this mechanism, DMF counters oxidative stress, reduces neuroinflammation, promotes mitochondrial quality control, and impedes pathological protein aggregation. These biological effects translate into the preservation of dopaminergic neurons and improvements in motor behavior in animal models. Although direct clinical evidence of DMF's efficacy in PD patients is currently very limited, early mechanistic human studies provide indirect support for the targeting of the Nrf2 pathway in PD. Furthermore, DMF's neuroprotective properties extend to other neurodegenerative diseases, underscoring its broader therapeutic potential. In conclusion, the strong preclinical foundation, combined with an established clinical safety record, makes DMF an attractive candidate for repurposing as a disease-modifying therapy for PD. Future clinical trials will be essential to validate these preclinical promises and define DMF's role in the management of PD.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-21.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 9","pages":"443-451"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mulberry leaf extracts and quercetin glycosides promote glycogen accumulation in astrocytes.","authors":"H Arie, K Nishioka, T Azuma, T Yamagaki, T Suzuki, Y Nakamura, N Murayama","doi":"10.26355/eurrev_202509_37402","DOIUrl":"https://doi.org/10.26355/eurrev_202509_37402","url":null,"abstract":"<p><p>OBJECTIVE: The astrocyte-neuron lactate shuttle is the mechanism by which astrocytic lactate is transferred to neurons to maintain brain function and is modulated by astrocytic glycogen content. The aims of this study were to determine whether mulberry leaf extracts promote astrocytic glycogen accumulation and to explore the active compounds of mulberry leaf extracts. MATERIALS AND METHODS: Glycogen content was determined in human-induced pluripotent stem cell-derived astrocytes treated with mulberry leaf extracts or their active compounds. To determine the involvement of active compounds in glycogen synthesis and degradation, human-induced pluripotent stem cell-derived astrocytes were treated with glucose-free medium containing 13C-glucose, and the amounts of 12C- and 13C-glucose in glycogen were quantified. RESULTS: Mulberry leaf extracts promoted astrocytic glycogen accumulation. Iminosugars in mulberry leaf extracts did not significantly increase the glycogen content of astrocytes. In contrast, several quercetin glycosides exhibited some of the activities of the mulberry leaf extracts. Quercetin aglycone, the basic backbone structure without glycosides, increased astrocytic glycogen content. Additionally, quercetin aglycone increased both 12C- and 13C-glucose contents, meaning it promoted glycogen synthesis and inhibited glycogen breakdown. CONCLUSIONS: In this study, quercetin glycosides were identified as active compounds present in mulberry leaf extracts. The principal compound responsible for the activity was identified as quercetin aglycone. Mulberry leaf extracts and quercetin analogs may induce astrocyte-neuron lactate shuttling by promoting the accumulation of glycogen in astrocytes.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-2.png.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 9","pages":"425-433"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective and safe use of alirocumab in spinal and bulbar muscular atrophy with high cardiovascular risk: a case report.","authors":"S Muscoli, L Colarocchio, D Koukorini, G di Bartolomeo, L Renzi, F Pocelli, R Desimone, F Moretti, G Gentile, G Pino, A Novelli, A Natale, G M Sangiorgi","doi":"10.26355/eurrev_202508_37357","DOIUrl":"https://doi.org/10.26355/eurrev_202508_37357","url":null,"abstract":"<p><p>BACKGROUND: Spinal and bulbar muscular atrophy (SBMA) is a rare X-linked neuromuscular disorder characterized by progressive muscle weakness and endocrine abnormalities. Beyond its classic neurological presentation, SBMA is increasingly associated with metabolic and cardiovascular comorbidities, including dyslipidemia and insulin resistance.   CASE REPORT: We present the case of a 54-year-old male with genetically confirmed SBMA and high cardiovascular risk, in whom statins and ezetimibe were contraindicated due to persistently elevated creatine kinase levels and underlying muscle involvement. Coronary CT angiography revealed subclinical atherosclerosis. Alirocumab, a PCSK9 inhibitor, was initiated at a dose of 150 mg every 2 weeks. After six months, LDL cholesterol was reduced by 54.9% without adverse effects or functional decline, and CK levels remained stable.   CONCLUSIONS: This case highlights the potential role of PCSK9 inhibitors as a safe and effective lipid-lowering option in patients with neuromuscular disorders at high cardiovascular risk, for whom traditional therapies are not feasible. It also highlights the importance of integrated cardiovascular care in managing multisystem diseases, such as SBMA.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-2-1.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 8","pages":"383-386"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Long noncoding RNA MNX1-AS1 overexpression promotes the invasion and metastasis of gastric cancer through repressing CDKN1A.","authors":"J-X Ma, Y-L Yang, X-Y He, X-M Pan, Z Wang, Y-W Qian","doi":"10.26355/eurrev_202508_37366","DOIUrl":"https://doi.org/10.26355/eurrev_202508_37366","url":null,"abstract":"<p><p>The article \"Long noncoding RNA MNX1-AS1 overexpression promotes the invasion and metastasis of gastric cancer through repressing CDKN1A\" by J.-X. Ma, Y.-L. Yang, X.-Y. He, X.-M. Pan, Z. Wang, Y.-W. Qian, published in Eur Rev Med Pharmacol Sci 2019; 23 (11): 4756-4762 DOI: 10.26355/eurrev_201906_18057-PMID: 31210302 has been retracted by in accordance with the Publisher and the Editor in Chief. Following some concerns on PubPeer, the authors were informed of the ongoing investigation and were asked to provide original data and clarify several other issues but remained unresponsive. The journal's investigation confirmed the duplication detected in Figure 3C and D and therefore the manuscript is retracted for Figure duplication. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18057.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 8","pages":"382"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: atypical anti-SAE1 autoantibody manifestation with splinter hemorrhages as onset, and related to urothelial cancer.","authors":"A Biglia, M C Sacchi, F Maggiore, V Morandi, E Cammarata, M M Ciriello, M R Pellico, L Agatea, C Pelazza, A Roveta, L M Castello","doi":"10.26355/eurrev_202508_37360","DOIUrl":"10.26355/eurrev_202508_37360","url":null,"abstract":"<p><p>BACKGROUND: Subungual splinter hemorrhages may represent an expression of infective endocarditis as well as autoimmune diseases or neoplasms. Anti-SAE1 autoantibody is directed against a small ubiquitin-like modifier-activating enzyme that plays a role in regulating transcription, cell cycle, and apoptosis. It is specific for dermatomyositis with skin rash and mild muscle involvement, and it can be associated with cancer.  CASE REPORT: We describe the case of a patient who developed subungual splinter hemorrhages and acrocyanosis. Infections were excluded, and autoimmunity resulted in anti-SAE1 autoantibodies. A cancer screening found a high-grade urothelial carcinoma. The splinter hemorrhages disappeared after the carcinoma enucleation.  CONCLUSIONS: Our case describes an atypical onset of anti-SAE1 dermatomyositis with splinter hemorrhages, potentially linked to urothelial cancer. This highlights the importance of comprehensive cancer screening in patients with unusual dermatomyositis presentations.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-rev.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 8","pages":"398-403"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Serum irisin levels in colorectal cancer patients.","authors":"Z Celik, N K Baygutalp, A F Kilic, S B Tekin, E Bakan, M A Gul, N Yuce","doi":"10.26355/eurrev_202508_37364","DOIUrl":"https://doi.org/10.26355/eurrev_202508_37364","url":null,"abstract":"<p><p>Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (4): 1474-1479-DOI: 10.26355/eurrev_202302_31387-PMID: 36876687 published online on 1 March 2023.  This erratum serves to include the ethics approval date and approval number, which were unintentionally omitted from the originally published online version of the article.  Therefore, the Ethics Approval statement has been corrected as follows:  Institutional ethics approval was obtained from the Clinical Research Ethics Committee of the Faculty of Medicine, Ataturk University on May 30, 2019, with approval number 241, and informed consent was provided by all the participants.  There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.  https://www.europeanreview.org/article/31387.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 8","pages":"381"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological evaluations of a series of socket preservation procedures using tooth as graft material.","authors":"P Cavellini, L Andreatta, F Alì, G Bavetta, P Veruggio, A Cesca, D Righi, V Farina, M Berardini, M Iorio, C Zambelli, M Iorio, F Gianfreda, A Palermo, E Minetti","doi":"10.26355/eurrev_202508_37370","DOIUrl":"10.26355/eurrev_202508_37370","url":null,"abstract":"<p><p>OBJECTIVE: In this multicenter study, we assessed the effectiveness of a novel autologous bone substitute obtained directly from the processing of extracted teeth. A total of 34 consecutive tooth grafting procedures were performed.  MATERIALS AND METHODS: Immediately following atraumatic extraction for restorative or endodontic purposes, the bone defect was filled and covered with an Osseoguard© membrane, using autologous material derived from the extracted tooth. Zimvie T3 PRO© implants with platform switching were placed in 34 patients.   RESULTS: After a 5-month healing period, the defects were significantly filled with newly formed hard tissue. Bone biopsies were subsequently taken during dental implant placement to assess histological outcomes. The tissue demonstrated a density comparable to medium-density bone, with a homogeneous and uniform appearance, showing no visible signs of inflammation. The post-operative healing phase was uneventful, with no infectious complications or evidence of graft particles within the regenerated bone structure. Histomorphometric analyses revealed the following results: average bone volume (BV) of 52.35% (±17.25). The average residual graft (RG) rate was 10.79% (±12.26), while new bone (NB) accounted for 41.56% (±22.02) of the samples.  CONCLUSIONS: Bone grafts resorb very quickly, while xenograft materials maintain space over time, facilitating bone regeneration. Unfortunately, xenograft materials are not osteoinductive, meaning they do not stimulate bone growth; rather, they provide a supportive structure for new bone formation. The findings of the current study revealed a significant increase in three-dimensional bone volume and a substantial percentage of vital bone formation across all socket preservation sites. The possibility of transforming the extracted tooth of the patient chairside into suitable osteoinductive grafting material offers interesting perspectives in the field of bone regeneration for dental implant purposes. The study demonstrated successful bone healing in guided regenerative surgery procedures utilizing autologous tooth grafts. However, further research with an extended follow-up period is necessary to fully evaluate the potential of demineralized dentin autografts.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/14062-Graphical-abstract-1-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 8","pages":"404-413"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}